Look at revenues 
Revenues largely from one drug highest risk
Add in sentiment already weakening 
=
Sharp likely drop imo

Add in CMS hates $NVO and highlighted all forms at top 🤣 

I'm not a fan of IRA, especially pill penalty, but if in future a company has multiple drugs, or similar setup, likely play.

Companies tend to not have data post JPM when announcement is made to limit upside.

This and a few other things were my thoughts, basically low upside, high downside.

Looks like it dropped almost 7% so $25.64BN lost.

Another heightened risk for $NVO is that hedge funds parked in it because it was considered safe. So likely see continued selling when they realize the extent to which it is cooked.

NFA 

Dr. DD